Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.31 USD | -1.69% | -4.45% | -47.91% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.91% | 2.69B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.92% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- ACADIA Pharmaceuticals : Morgan Stanley Adjusts ACADIA Pharmaceuticals' Price Target to $58 From $57, Keeps at Overweight